Taking into account these and our previous data showing the ability of β3-AR blockade to elicit an immune competent TME in melanoma-bearing mice [13], we wondered whether, in NB tumor, the β3-AR antagonism could lead to immune response activation dependent on PD-L1 signaling involvement. The gene discussed is ADRB3; the disease is melanoma.